OptiBiotix Health PLC Exercise of Options & Director's Dealing (2070D)

TIDMOPTI

RNS Number : 2070D

OptiBiotix Health PLC

08 October 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Exercise of Options, Director's Dealing and Issue of Equity

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, received notification on Friday 5 October 2018 for the exercise of options over 357,722 ordinary shares in the Company at an exercise price of 20p per share providing the Company with proceeds of GBP71,554.

The option holder, Dr Gareth Barker, a Non-executive Director of the Company, has undertaken not to dispose of the 357,722 ordinary shares for twelve months. Dr Barker has further agreed that he will only dispose of shares through the Company's broker. After the twelve month period, the undertaking will no longer be in place.

Application will be made to the London Stock Exchange to admit the 357,722 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 11 October 2018. The new ordinary shares will rank pari passu with the existing ordinary shares.

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 84,724,363 ordinary shares of 2p each. There are no ordinary shares held in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Mark Collingbourne, Chief Financial Officer.

For further information, please contact:

 
 OptiBiotix Health plc                                                www.optibiotix.com 
 Stephen O'Hara, Chief Executive                              Contact via Walbrook below 
 
 Cairn Financial Advisers LLP                                         Tel: [phone] 
 Liam Murray / Jo Turner 
 
 finnCap (Broker)                                                     Tel: [phone] 
 Adrian Hargrave / Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Abigail Wayne (Corporate Broking) 
 
 Walbrook PR Ltd                         Tel: [phone] or [e-mail] 
 Anna Dunphy                                                          Mob: [phone] 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1       Details of the person discharging managerial responsibilities/person 
          closely associated 
        ------------------------------------------------------------------------------------------------- 
 a.      Name                                     Dr Gareth Barker 
        ---------------------------------------  -------------------------------------------------------- 
 2       Reason for notification 
        ---------------------------------------  -------------------------------------------------------- 
 a.      Position/Status                          Non-executive Director of the Company 
        ---------------------------------------  -------------------------------------------------------- 
 b.      Initial notification/                    Initial Notification 
          Amendment 
        ---------------------------------------  -------------------------------------------------------- 
 3       Details of the issuer, emission allowance market participant, 
          auction platform, auctioneer or auction monitor 
        ------------------------------------------------------------------------------------------------- 
 a.      Name                                     OptiBiotix Health Plc 
        ---------------------------------------  -------------------------------------------------------- 
 b.      LEI                                      213800UKYQFT941QHS14 
        ---------------------------------------  -------------------------------------------------------- 
 4       Details of the transaction(s): section to be repeated for 
          (i) each type of instrument; (ii) each type of transaction; 
          (iii) each date; and (iv) each place where transactions have 
          been conducted 
        ------------------------------------------------------------------------------------------------- 
 a.      Description of 
          the financial                            Options over 357,722 ordinary shares of 
          instrument, type                         2p each 
          of instrument 
 
          Identification 
          Code                                     ISIN: GB00BP0RTP38 
        ---------------------------------------  -------------------------------------------------------- 
 b.      Nature of the                            Exercise of options to purchase ordinary 
          transaction                              shares of the Company. Following the transaction, 
                                                   Dr Gareth Barker has an interest in 357,722 
                                                   ordinary shares. 
        ---------------------------------------  -------------------------------------------------------- 
 
 c.      Price(s) and volume(s)                   Price(s) per                    Volume(s) 
                                                   share 
        ---------------------------------------  ------------------------------ 
                                                  20p                             357,722 
                                                 ------------------------------  --------------------- 
 
         Aggregated information 
 
          - Aggregated Volume                       357,722 
 
 d.       - Price                                   20p 
        ---------------------------------------  -------------------------------------------------------- 
 e.      Date of the transaction                  5 October 2018 
        ---------------------------------------  -------------------------------------------------------- 
 f.      Place of the transaction                 London Stock Exchange, AIM 
        ---------------------------------------  -------------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCMMMGGZNFGRZZ

(END) Dow Jones Newswires

October 08, 2018 02:00 ET (06:00 GMT)